ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This pilot trial explores a non-drug neuromodulation approach (auricular vagus nerve stimulation) that might influence brain–gut interactions, stress, fatigue, and quality of life in people with IBD in remission. Findings could inform larger studies of neuromodulation as a supportive intervention.
Who Should Pay Attention
Adult patients with Crohn's disease or ulcerative colitis (particularly those interested in non-pharmacological neuromodulation), gastroenterology clinicians, and researchers studying brain–gut interactions or neuromodulation.
Study Snapshot
Story typeClinical Reference
Trial phaseEarly Phase 1
Enrollment15 participants
Study statusEnrolling_by_invitation
Source depthTrial registry record
What To Know
The VIBRANT-IBD study is a small (≈15 participants), single-arm pilot enrolling adults with IBD in remission.
Participants will self-administer auricular transcutaneous vagus nerve stimulation daily for 28 days using the Nurosym device and complete resting-state and structural MRI scans before and after the intervention, along with standardised psychological questionnaires.
The main goals are feasibility, acceptability, safety, and preliminary neurofunctional and neuropsychological effects rather than clinical efficacy on gut inflammation.
The study may help clarify brain–gut interactions and whether non-invasive neuromodulation affects brain networks and patient-reported outcomes in IBD, but as an early-phase pilot it is not designed to show definitive clinical benefit.
Keep In Mind
Structured content depth: trial-record. This entry is a clinicaltrials.gov registration for an early-phase, single-arm feasibility study; it describes planned methods and outcomes but does not report study results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of Gdansk
Trial IDNCT07636304
Study typeInterventional
Trial phaseEarly Phase 1
Enrollment15 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 11, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
INTERROGATING GCPII-MEDIATED GLUTAMATE SIGNALING IN THE GASTROINTESTINAL TRACT AND ITS ROLE IN INTESTINAL HOMEOSTASIS
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Spleen volume in relation to ulcerative colitis and Crohn's disease: a Mendelian randomization study
The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...
Fibroblast Activation Protein Expression Differs Between Inflamed and Fibrostenotic Inflammatory Bowel Disease
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.